Mifepristone 200 mg + Misoprostol Regimen for MTP at 20 Weeks

Context and Legal Framework (India)

Standard Regimen (WHO 2018 / Evidence-Based)

WHO 2018 Safe Abortion Guideline: Mifepristone 200 mg orally followed 1-2 days later by misoprostol 400 mcg vaginally or sublingually every 3 hours (up to 5 doses). The 800 mcg loading dose previously recommended in 2012 is no longer considered necessary for ≥12 weeks gestation.

Important Dosing Nuances at 20 Weeks

• Mifepristone 200 mg is as effective as 600 mg when combined with misoprostol - the FDA-approved 600 mg dose was for early pregnancy (<49 days) without misoprostol backup. At 20 weeks, 200 mg is the standard globally (Goodman & Gilman's, p. 3677).

• Vaginal = most efficacious with fewest GI side effects; preferred route
• Sublingual = effective but higher incidence of systemic side effects (fever, chills, GI symptoms)
• Buccal = acceptable alternative, intermediate side-effect profile

• 48 hours is superior to 24 hours at this gestation. A 2025 Lancet Global Health RCT (Endler et al., ISRCTN49711891, n=531, 9-20 weeks, India/Sweden/Thailand/Vietnam) showed 24-h interval had only 89% vs 94% success within 12 hours with a 48-h interval - the 24-h interval was not non-inferior. The 48-h interval is preferred for better outcomes.
• The study used: 200 mg mifepristone oral → 800 mcg misoprostol vaginally (first dose) → 400 mcg sublingually every 3 h thereafter.

• At ≥17 weeks, the uterus is more sensitive to prostaglandins; some protocols use 200 mcg vaginally every 6 hours (lower dose, longer interval) to reduce risk of uterine hyperstimulation and cervical laceration
• Higher-dose/frequent regimens (400 mcg every 3 h): faster IAI (induction-abortion interval ~6-10 h), higher success but more side effects and rare uterine rupture risk - especially in women with prior uterine scars

Common Indian Hospital Protocol (13-20 Weeks)

1. Day 1: Mifepristone 200 mg orally
2. Day 3 (48 h later):
   • Loading dose: Misoprostol 400 mcg vaginally (in women 13-16 weeks) OR 200 mcg vaginally (in multiparous women at 17-20 weeks)
   • Subsequent doses: Misoprostol 200 mcg vaginally every 6 hours, up to 3-5 doses
3. Monitor for fetal/placental expulsion
4. Confirm complete expulsion; evacuate retained products if needed

Pre-procedure Considerations

• Cervical priming: Osmotic dilators (laminaria/Dilapan) 12-24 h before misoprostol are used at some centers at >16 weeks to shorten induction time and reduce complications
• Oxytocin augmentation: IV oxytocin can be added if uterine contractions are inadequate after misoprostol
• Analgesia: Paracetamol + NSAID (ibuprofen/diclofenac) orally; stronger opioid analgesia may be needed at 20 weeks
• Antibiotic prophylaxis: Doxycycline 200 mg or azithromycin 500 mg is commonly given
• Anti-D immunoglobulin: For Rh-negative women (300 mcg IM)

Contraindications to Mifepristone

• Confirmed or suspected ectopic pregnancy
• Chronic adrenal failure
• Long-term corticosteroid therapy
• Known coagulopathy or anticoagulant therapy
• IUD in situ (remove first)
• Allergy to mifepristone or misoprostol

Adverse Effects to Monitor

Efficacy Summary

• Complete abortion rate: >95-99% with mifepristone + misoprostol at 13-20 weeks (vs. ~78-88% with misoprostol alone)
• Need for surgical intervention: ~1-5%
• The 2025 systematic review in Cochrane (Atrio et al., PMID 40626417) confirms medical methods are as effective as surgical D&E in the second trimester with comparable complication rates

Key References

• WHO Safe Abortion Technical Guidance, 2018 (updated from 2012)
• Goodman & Gilman's Pharmacological Basis of Therapeutics - Termination of Pregnancy, p. 3677
• Endler M et al., Lancet Glob Health 2025 (PMID 39706648) - 24 h vs 48 h mifepristone-misoprostol interval RCT
• Medical regimens for abortion ≥12 weeks: systematic review, PMC7484538 - supports mifepristone 200 mg + misoprostol 400 mcg vaginally every 3 h as optimal
• Berek & Novak's Gynecology - Second-Trimester Abortion chapter